Lynn Welter

University of Luxembourg, Life Sciences Research Unit


Photo of Lynn Welter


The impact of PPAR signaling on Alzheimer's disease


Epidemiological studies have demonstrated that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs) decrease the risk for developing Alzheimer's disease (AD). However, the mechanism behind these NSAIDs is still controversial. A subset of NSAIDs activate the peroxisome proliferator-activated receptor-g (PPARg). PPARg is a ligand-activated transcription factor that belongs to the superfamily of nuclear receptors. The activation of PPARg has been associated with potent anti-inflammatory as well as anti-amyloidogenic effects in cell culture and AD animal models. Unfortunately, very little is known about the molecular mechanisms that subserve these effects. Our team tries to identify and characterize primary PPAR target genes in microglia and neuronal cells which we think is important for the development of new therapeutic strategies and targets for the treatment of AD.


For the latest project poster please see the Documents below

Related Files

Click a category or sub category name to show the files in that category. Download/view a file by clicking its title.

Files for this page
Files for this page

Keep reading in this section...